The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Beam Therapeutics Inc. | COM | 07373V105 | 205,573 | 2,362,635 | SH | DFND | 1 | 2,362,635 | 0 | 0 | |
LYELL IMMUNOPHARMA INC | COM | 55083R104 | 300,418 | 20,298,522 | SH | DFND | 1 | 20,298,522 | 0 | 0 | |
RELX PLC | SPONSORED ADR | 759530108 | 181,952 | 40,254,832 | SH | DFND | 1 | 40,254,832 | 0 | 0 | |
Illumina Inc | COM | 452327109 | 136,732 | 337,102 | SH | DFND | 1 | 337,102 | 0 | 0 |